Paper37631925
A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma.
Tojjari A and 5 others. Vaccines (Basel), 2023. Cited by 43 papers, by iCite.
Cite this record
ConductScience Library. A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma. Papers, record 37631925. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37631925
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References80
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26214521 | Therapeutic cancer vaccines. | J Clin Invest | 2015 | https://conductscience.org/library/papers/26214521 | PubMed |
| 2 | 31646087 | Trial watch: dendritic cell vaccination for cancer immunotherapy. | Oncoimmunology | 2019 | https://conductscience.org/library/papers/31646087 | PubMed |
| 3 | 30072299 | Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis. | Cytotherapy | 2018 | https://conductscience.org/library/papers/30072299 | PubMed |
| 4 | 33376523 | Myeloid and plasmacytoid dendritic cell combined vaccines loaded with heat-treated tumor cell lysates enhance antitumor activity in murine lung cancer. | Oncol Lett | 2021 | https://conductscience.org/library/papers/33376523 | PubMed |
| 5 | 26556756 | Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice. | PLoS One | 2015 | https://conductscience.org/library/papers/26556756 | PubMed |
| 6 | 25994219 | Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/β-catenin signalling pathway via suppression of activator protein 2α. | Gut | 2016 | https://conductscience.org/library/papers/25994219 | PubMed |
| 7 | 29961183 | Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma. | Am J Clin Dermatol | 2018 | https://conductscience.org/library/papers/29961183 | PubMed |
| 8 | 28669112 | Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. | BioDrugs | 2017 | https://conductscience.org/library/papers/28669112 | PubMed |
| 9 | 25873455 | Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. | J Surg Oncol | 2015 | https://conductscience.org/library/papers/25873455 | PubMed |
| 10 | 19966816 | Viruses as vaccine vectors for infectious diseases and cancer. | Nat Rev Microbiol | 2010 | https://conductscience.org/library/papers/19966816 | PubMed |
| 11 | 29567706 | Personalized vaccines for cancer immunotherapy. | Science | 2018 | https://conductscience.org/library/papers/29567706 | PubMed |
| 12 | 29344179 | In vivo antitumor activity evaluation of cancer vaccines prepared by various antigen forms in a murine hepatocellular carcinoma model. | Oncol Lett | 2017 | https://conductscience.org/library/papers/29344179 | PubMed |
| 13 | 26014293 | Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26014293 | PubMed |
| 14 | 30061739 | Molecular therapies and precision medicine for hepatocellular carcinoma. | Nat Rev Clin Oncol | 2018 | https://conductscience.org/library/papers/30061739 | PubMed |
| 15 | 30258449 | Activation of RIG-I-Mediated Antiviral Signaling Triggers Autophagy Through the MAVS-TRAF6-Beclin-1 Signaling Axis. | Front Immunol | 2018 | https://conductscience.org/library/papers/30258449 | PubMed |
| 16 | 18980227 | A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. | Hepatology | 2009 | https://conductscience.org/library/papers/18980227 | PubMed |
| 17 | 31886313 | Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses In Vitro. | J Immunol Res | 2019 | https://conductscience.org/library/papers/31886313 | PubMed |
| 18 | 30710128 | Adeno-associated virus vector as a platform for gene therapy delivery. | Nat Rev Drug Discov | 2019 | https://conductscience.org/library/papers/30710128 | PubMed |
| 19 | 32421952 | Nanoparticulate Carriers Used as Vaccine Adjuvant Delivery Systems. | Crit Rev Ther Drug Carrier Syst | 2019 | https://conductscience.org/library/papers/32421952 | PubMed |
| 20 | 27039170 | High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. | Eur J Cancer | 2016 | https://conductscience.org/library/papers/27039170 | PubMed |
Cited by35
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 43 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42652118 | Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies. | Biomedicines | 2026 | https://conductscience.org/library/papers/42652118 | PubMed |
| 42293741 | Lipid nanoparticles and extracellular vesicles: emerging cell free therapeutic platforms for hepatobiliary cancers. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42293741 | PubMed |
| 42220430 | Current and Future Landscape of Hepatocellular Carcinoma Treatment. | Oncol Res | 2026 | https://conductscience.org/library/papers/42220430 | PubMed |
| 42087213 | Personalized immunotherapy in HCC: synthesis, delivery, and clinical progress of mRNA-based vaccines. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42087213 | PubMed |
| 42079726 | Blood protein biomarkers in hepatocellular carcinoma: progress and challenges. | PeerJ | 2026 | https://conductscience.org/library/papers/42079726 | PubMed |
| 41810102 | Tumor Vaccines in Hepatocellular Carcinoma: Advances, Challenges, and the Path Toward Precision Immunotherapy. | J Clin Transl Hepatol | 2026 | https://conductscience.org/library/papers/41810102 | PubMed |
| 41784912 | Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances. | Clin Exp Med | 2026 | https://conductscience.org/library/papers/41784912 | PubMed |
| 41780553 | Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy. | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/41780553 | PubMed |
| 41746109 | Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/41746109 | PubMed |
| 41614820 | Cancer Vaccines: Molecular Mechanisms, Clinical Progress, and Combination Immunotherapies with a Focus on Hepatocellular Carcinoma. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/41614820 | PubMed |
| 41327374 | Proteoglycan-4 potentiates the antitumor efficacy of regorafenib in an orthotopic model of hepatocellular carcinoma. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/41327374 | PubMed |
| 41201063 | The Immune Microenvironment in Liver Cancer: From Analysis to Targeting. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/41201063 | PubMed |
| 40861312 | A Patient Charter to Improve Care for Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2025 | https://conductscience.org/library/papers/40861312 | PubMed |
| 40854817 | Constructing the cure: engineering the next wave of antibody and cellular immune therapies. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40854817 | PubMed |
| 40767872 | mRNA vaccines for gastrointestinal cancers: a paradigm shift in treatment. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/40767872 | PubMed |
| 40660439 | Cancer Vaccines: Mechanisms, Clinical Applications, Challenges, and Future Directions in Precision Medicine. | Curr Cancer Drug Targets | 2026 | https://conductscience.org/library/papers/40660439 | PubMed |
| 40564910 | The Design of a Multistage Monitoring Protocol for Dendritic Cell-Derived Exosome (DEX) Immunotherapy: A Conceptual Framework for Molecular Quality Control and Immune Profiling. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40564910 | PubMed |
| 40500404 | Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy. | Cell Mol Immunol | 2025 | https://conductscience.org/library/papers/40500404 | PubMed |
| 40389815 | Heterogeneity and efficacy of immunotherapy in multiple cancer: insights from a meta-analysis. | Biol Proced Online | 2025 | https://conductscience.org/library/papers/40389815 | PubMed |
| 40266115 | Recent Advances in the Development and Efficacy of Anti-Cancer Vaccines-A Narrative Review. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/40266115 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| FOXP3 | 50943 | PubTator's text mining | https://conductscience.org/library/genes/50943 | NCBI Gene |
| GPC3 | 2719 | PubTator's text mining | https://conductscience.org/library/genes/2719 | NCBI Gene |
| IL2RA | 3559 | PubTator's text mining | https://conductscience.org/library/genes/3559 | NCBI Gene |
| MAGEA1 | 4100 | PubTator's text mining | https://conductscience.org/library/genes/4100 | NCBI Gene |
| NUSAP1 | 51203 | PubTator's text mining | https://conductscience.org/library/genes/51203 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37631925
GET https://conductscience.org/api/papers/v1/37631925/references?page=2